Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500989 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL1318390 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3276769 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3031676 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3033285 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3031679 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL16977621 | 0.84 | EPHX2 (0.34) | DPP7GAADPP4 | |
| SCHEMBL3025369 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 | |
| SCHEMBL3025364 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 | |
| SCHEMBL1314601 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| EP-1638959-B1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1641784-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-7205410-B2 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A | 2006-06-29 | — | — | US | disclosed |
| EP-1641784-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2004-03-25 | — | — | US | disclosed |
| EP-1000028-B1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | EP | disclosed |
| US-6635643-B2 | For treating conditions which are related to impairment of gastric emptying | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-10-21 | — | — | US | disclosed |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-09-25 | — | — | US | disclosed |
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-04-24 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | disclosed |
| US-6452013-B1 | FOR TREATING CONDITIONS WHICH ARE RELATED TO IMPAIRMENT OF GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-17 | — | — | US | disclosed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | disclosed |
| EP-1206938-A1 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, ALK, CBR1 | GABRR1 79/4885GABRR2 126/4885DPP7 1700/4885 |
| US-20060142342-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | GABRR1 38/4885GABRR2 66/4885DPP7 3703/4885 |
| US-20060142341-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, HRH4, HRH1 | GABRR1 39/4885GABRR2 66/4885DPP7 3700/4885 |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | HRH2, ALK, CBR1 | GABRR1 93/4885GABRR2 137/4885DPP7 1197/4885 |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | HTR4, HTR2B, TPH2 | GABRR1 453/4885GABRR2 362/4885DPP7 891/4885 |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | CBR1, ALK, CBR3 | GABRR1 25/4885GABRR2 32/4885DPP7 1510/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | GABRR1 502/4885GABRR2 505/4885DPP7 1072/4885 |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | ALK, HRH2, CBR1 | GABRR1 37/4885GABRR2 49/4885DPP7 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.